Emerging profile of cetuximab in non-small cell lung cancer

Lung Cancer

Volumn 68, Issue 3, 2010, Pages 332-337

  Ettinger, David S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Advanced NSCLC; Biologic therapy; Cetuximab; First line treatment; Survival

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; GENE MUTATION; HUMAN; HYPOMAGNESEMIA; INJECTION SITE REACTION; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; CARCINOMA, NON-SMALL-CELL LUNG; CARDIOVASCULAR DISEASES; COMORBIDITY; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; MORTALITY; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARDIOVASCULAR DISEASES; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COMORBIDITY; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; ANTIBODIES, MONOCLONAL, HUMANIZED;

EID: 77952542715     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.07.012     Document Type: Review

References (43)

1. Wells A. EGF receptor. Int J Biochem Cell Biol 1999, 31:637-643.
2. Yarden Y., Sliwkowski M.X. Untangling the ErbB signaling network. Nature Rev Mol Cell Biol 2001, 2:127-137.
3. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002, 7(Suppl. 7):2-8.
4. Salomon D.S., Brandt R., Ciardiello E., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19:183-232.
5. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005, 353:133-144.
6. Hirsch F.R., Varella-Garcia M., Bunn P.A., Franklin W.A., Dziadziuszko R., Thatcher N., et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006, 24:5034-5042.
7. Khambata-Ford S., Harbison C.T., Woytowitz D., Awad M., Horak C., Xu L.A., et al. K-Ras mutation (mut), EGFR-related, and exploratory markers as response predictors of cetuximab in first-line advanced NSCLC: retrospective analyses of the BMS099 trial. J Clin Oncol 2009, 27(15s):412s. [Abstract 8021].
8. Pirker R., Pereira J.R., Szczesna A., von Pawel J., Krzakowski M., Ramlau R., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373:1525-1531.
9. Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. J Clin Oncol 2005, 23:3235-3242.
10. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
11. Kim E., Hirsch V., Mok M., Socinski M.A., Gervais R., Wu Y.L., et al. Gefitinib verses docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
12. Herbst R.S., Prager D., Hermann R., Fehrenbacher L., Johnson B.E., Sandler A., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer. J Clin Oncol 2005, 23:5892-5899.
13. Gatzemeier U., Pluzanska A., Szcesna A., Kaukel E., Roubec J., De Rosa F., et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small cell lung cancer: the Tarceva Lung Cancer Investigation trial. J Clin Oncol 2007, 25:1545-1552.
14. Herbst R.S., Giaccone G., Schiller J.H., Natale R.B., Miller V., Manegold C., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004, 22:785-794.
15. Giaccone G., Herbst R.S., Manegold C., Scagliotti G., Rosell R., Miller V., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004, 22:777-784.
16. Goldstein N.I., Prewett M., Zuklys K., Rockwell P., Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995, 1:1311-1318.
17. Erbitux® (cetuximab). Package insert. Princeton, NJ: Bristol-Myers Squibb Company; November 2007.
18. Kurai J., Chikumi H., Hashimoto K., Yamaguchi K., Yamasaki A., Sako T., et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 2007, 13:1552-1561.
19. Jonker D.J., O'Callaghan C.J., Karapetis C.S., Zalcberg J.R., Tu D., Au H.J., et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357:2040-2048.
20. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
21. Vermorken J., Mesia R., Vega V., Remenar E., Hitt R., Kawecki A., et al. Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy - results of a randomized phase III (Extreme) study. J Clin Oncol 2007, 25(18S). [Abstract 6091].
22. Thienelt C.D., Bunn P.A., Hanna N., Rosenberg A., Needle M.N., Long M.E., et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer. J Clin Oncol 2005, 23:8786-8793.
23. Robert F., Blumenschein G., Herbst R.S., Fossella F.V., Tseng J., Saleh M.N. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol 2005, 23:9089-9096.
24. Borghaei H., Langer C.J., Millenson M., Ruth K.J., Litwin S., Tuttle H., et al. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017. J Thorac Oncol 2008, 3:1286-1292.
25. Belani C.P., Schreeder M.T., Steis R.G., Guidice R.A., Marsland T.A., Butler E.H., et al. Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study. Cancer 2008, 113:2512-2517.
26. Rosell R., Robinet G., Szczesna A., Ramlau R., Constenla M., Mennecier B.C., et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small cell lung cancer. Ann Oncol 2008, 19:362-369.
27. Butts C.A., Bodkin D., Middleman E.L., Englund C.W., Ellison D., Alam Y., et al. Randomized phase II study of gemcitabine plus cisplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non-small cell lung cancer. J Clin Oncol 2007, 25:5777-5784.
28. Herbst R.S., Chansky K., Kelly K., Atkins J.N., Davies A.M., Dakhil S.R., et al. A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): final report of SWOG 0342. J Clin Oncol 2007, 25(18S):395s. [Abstract 7545].
29. ®) in combination with taxane/carboplatin versus taxane/carboplatin alone as first-line treatment for patients with advanced/metastatic non-small cell lung cancer (NSCLC). J Thor Oncol 2007, 2(8):S340-S341.
30. Lynch TJ, Patel T, Dreisbach L, et al. Overall survival (OS) results from the phase III trial BMS099: cetuximab+taxane/carboplatin as 1st-line treatment for advanced NSCLC. Presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology; November 13-15, 2008; Chicago, IL.
31. Gatzemeier U, von Pawel J, Vynnchenko I, Zatloukal P, De Marinis F, O'Byrne K, et al. FLEX: Cetuximab in combination with platinum-based chemotherapy (CT) improves survival versus CT alone in the 1st-line treatment of patients with advanced non-small cell lung cancer (NSCLC). Presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology; November 13-15, 2008; Chicago, IL.
32. Blumenschein G.R., Paulus R., Curran W.J., Robert F., Fossella F.V., Werner-Wasik M., et al. A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (pts) with stage III A/B non-small cell lung cancer (NSCLC): a report of the 2 year and median survival (MS) for the RTOG 0324 trial. J Clin Oncol 2008, 26(May (Suppl.)). [Abstract 7516].
33. Govindan R., Bogart J., Wang X., Hodgson L., Kratzke R., Vokes E.E., et al. Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407. J Clin Oncol 2009, 27(15S). [Abstract 7505].
34. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 2006, 355:2542-2550.
35. Hanna N., Lilenbaum R., Ansari R., Lynch T., Govindan R., Jänne P.A., et al. Phase II trial of cetuximab in patients with previously treated non-small cell lung cancer. J Clin Oncol 2006, 24:5253-5258.
36. Hirsch F.R., Herbst R.S., Olsen C., Chansky K., Crowley J., Kelly K., et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008, 26:3351-3357.
37. O'Byrne K.J., Bondarenko I., Barrios C., Eschbach C., Martens U., Hotko Y., et al. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): data from the FLEX study. J Clin Oncol 2009, 27(15S). [Abstract 8007].
38. Van Cutsem E., Lang I., D'haens G., Moiseyenko V., Zaluski J., Folprecht G., et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol 2008, 26(May (Suppl.)). [Abstract 2].
39. Bokemeyer C., Bondarenko I., Hartmann J.T., De Braud F.G., Volovat C., Nippgen J., et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab; the OPUS experience. J Clin Oncol 2008, 26(May (Suppl.)). [Abstract 4000].
40. Eberhard D.A., Johnson B.E., Amler L.C., Goddard A.D., Heldens S.L., Herbst R.S., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005, 23:5900-5909.
41. Zhu C.-Q., da Cunha Santos G., Ding K., Sakurada A., Cutz J.C., Liu N., et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR, 21. J Clin Oncol 2008, 26:4268-4275.
42. Miller V.A., Riely G.J., Zakowski M.F., Li A.R., Patel J.D., Heelan R.T., et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008, 26:1472-1478.
43. Mack P.C., Holland W.S., Redman M., Lara P.N., Snyder L.J., Hirsch F.R., et al. KRAS mutation analysis in cetuximab-treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342 and S0536. J Clin Oncol 2009, 27(15S). [Abstract 8022].